Supported by Genentech/Roche.
The figures were created with Biorender.com.
Disclosure: K. Yoshida, Genentech/Roche (E, I); N. Anegondi, Genentech/Roche (E, I), “Multimodal prediction of geographic atrophy growth rate” (P), “Multimodal geographic atrophy lesion segmentation” (P); A. Pely, Genentech/Roche (C); M. Zhang, Genentech/Roche (E, I); F. Debraine, Genentech/Roche (E); K. Ramesh, Genentech/Roche (E); V. Steffen, Genentech/Roche (E, I); S.S. Gao, Genentech/Roche (E, I), “Multimodal prediction of geographic atrophy growth rate” (P); C. Cukras, Genentech/Roche (E, I); C. Rabe, Genentech/Roche (E, I); D. Ferrara, Genentech/Roche (E, I); R.F. Spaide, Roche (C), Regeneron (C), Heidelberg (C), Topcon (C), Bayer (C), Topcon Medical Systems (R); S.R. Sadda, Allergan/AbbVie (C), Apelis (C), Alnylam (C), Amgen (C), Iveric Bio (C), Roche/Genentech (C), Novartis (C), Nanoscope (C), CharacterBio (C), Neurotech (C), NotalVision (C), Eyepoint (C), OcularTx (C), Alkeus (C), 4DMT (C), Oxurion (C), Optos (C), Heidelberg Engineering (C, R, F), iCare (C, F), Novartis (R), Optos (R, F), Carl Zeiss Meditec (R, F), Nidek (R, F), Regeneron (S), RegenxBio (S), Topcon (F); F.G. Holz, Genentech Inc. (F), Bayer (F), Heidelberg Engineering (F, C, R), Zeiss (F, C, R), Optos (F), Apellis (F, C, R), IvericBio/Astellas (F), Novartis (F, C, R), Pixium Vision (F), Bayer (C), Genentech Inc. (C), IvericBio/Astellas (C), Pixium Vision (C), Oxurion (C), Jansen (C); Q. Yang, Genentech/Roche (E, I), “Multimodal prediction of geographic atrophy growth rate” (P)